Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.

Literature DB >> 26337354

Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma.

Heike Richly¹, Tae Min Kim², Martin Schuler¹, Dong-Wan Kim², Simon J Harrison³, Alice T Shaw⁴, Anthony L Boral⁵, Alejandro Yovine⁶, Benjamin Solomon³.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2015 PMID： 26337354 PMCID： PMC4559938 DOI： 10.1182/blood-2014-12-617779

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

8 in total

1. Crizotinib in anaplastic large-cell lymphoma.

Authors: Carlo Gambacorti-Passerini; Cristina Messa; Enrico M Pogliani
Journal: N Engl J Med Date: 2011-02-24 Impact factor: 91.245

2. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Authors: Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Yin Yang; Eric L Sievers; Dana A Kennedy; Andrei Shustov
Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544

3. Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors: Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245

4. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Authors: Thomas H Marsilje; Wei Pei; Bei Chen; Wenshuo Lu; Tetsuo Uno; Yunho Jin; Tao Jiang; Sungjoon Kim; Nanxin Li; Markus Warmuth; Yelena Sarkisova; Frank Sun; Auzon Steffy; AnneMarie C Pferdekamper; Allen G Li; Sean B Joseph; Young Kim; Bo Liu; Tove Tuntland; Xiaoming Cui; Nathanael S Gray; Ruo Steensma; Yongqin Wan; Jiqing Jiang; Greg Chopiuk; Jie Li; W Perry Gordon; Wendy Richmond; Kevin Johnson; Jonathan Chang; Todd Groessl; You-Qun He; Andrew Phimister; Alex Aycinena; Christian C Lee; Badry Bursulaya; Donald S Karanewsky; H Martin Seidel; Jennifer L Harris; Pierre-Yves Michellys
Journal: J Med Chem Date: 2013-06-26 Impact factor: 7.446

5. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

Authors: Kerry J Savage; Nancy Lee Harris; Julie M Vose; Fred Ullrich; Elaine S Jaffe; Joseph M Connors; Lisa Rimsza; Stefano A Pileri; Mukesh Chhanabhai; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger
Journal: Blood Date: 2008-04-02 Impact factor: 22.113

6. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.

Authors: Vivien Mak; Jeremey Hamm; Mukesh Chhanabhai; Tamara Shenkier; Richard Klasa; Laurie H Sehn; Diego Villa; Randy D Gascoyne; Joseph M Connors; Kerry J Savage
Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544

7. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Authors: Julie Vose; James Armitage; Dennis Weisenburger
Journal: J Clin Oncol Date: 2008-07-14 Impact factor: 44.544

8. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.

Authors: Carlo Gambacorti Passerini; Francesca Farina; Alessandra Stasia; Sara Redaelli; Monica Ceccon; Luca Mologni; Cristina Messa; Luca Guerra; Giovanni Giudici; Elena Sala; Lara Mussolin; Dries Deeren; Michael H King; Michael Steurer; Rainer Ordemann; Amos M Cohen; Matthias Grube; Lea Bernard; Gianpaolo Chiriano; Laura Antolini; Rocco Piazza
Journal: J Natl Cancer Inst Date: 2014-02 Impact factor: 13.506

8 in total

13 in total

Review 1. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors: Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal: J Clin Exp Hematop Date: 2017

2. Alectinib, Ceritinib, Elotuzumab, and Venetoclax.

Authors: J Aubrey Waddell; Dominic A Solimando
Journal: Hosp Pharm Date: 2016-07

Review 3. Targeting ALK: Precision Medicine Takes on Drug Resistance.

Authors: Jessica J Lin; Gregory J Riely; Alice T Shaw
Journal: Cancer Discov Date: 2017-01-25 Impact factor: 39.397

4. Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies.

Authors: Jerold Loh; Yvonne Li En Ang; Amit Jain; Joe Yeong; Raghav Sundar
Journal: JCO Precis Oncol Date: 2022-07

Review 5. ALK-positive primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature.

Authors: Shamir Geller; Theresa N Canavan; Melissa Pulitzer; Alison J Moskowitz; Patricia L Myskowski
Journal: Int J Dermatol Date: 2017-10-23 Impact factor: 2.736

6. Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas.

Authors: Zachary D Epstein-Peterson; Steven M Horwitz
Journal: Semin Hematol Date: 2021-03-03 Impact factor: 3.851

7. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions.

Authors: Chen Fu; Dan S Gombos; Jared Lee; Goldy C George; Kenneth Hess; Andrew Whyte; David S Hong
Journal: Oncotarget Date: 2017-05-05